Repaglinide is an anti-diabetic medication that is used to treat type II diabetes. Repaginate is a class II biopharmaceutical chemical (BCS) chemical. It is lipophilic, has a short half-life (1 hour), and doesn't dissolve well in water. Only around 55% of medications with a high metabolism in the first pass may be taken by mouth. Repaglinide has a half-life of one hour, and because of first-pass metabolism, it is 56% bioavailable in the body. Repaglinide has to be taken often since the total daily dose is 16 mg (for example, 4 mg four times a day, depending on how you eat). Repaglinide transdermal patches were designed to sustain medication release, improve drug bioavailability, and boost patient adherence. A transdermal patch of Repaglinide was developed to keep the drug's release going and make it easier for patients to use. By changing the grades of HPMC and the amount of PVP K30 used in the solvent casting process, we made several formulations. We tested the generated formulations for a number of things, including thickness, tensile strength, folding endurance, % elongation, % moisture content, % moisture absorption, % drug content, in vitro drug release, in vitro permeation, and drug excipient compatibility.